Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
Boekholdt
S Matthijs
SM
de Winter
Robbert J
RJ
Kastelein
John J P
JJ
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001547:Benzaldehydes / Q000627:therapeutic use; D002317:Cardiovascular Agents; D003327:Coronary Disease / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D010091:Oximes / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000893:Anti-Inflammatory Agents; D001547:Benzaldehydes; D002317:Cardiovascular Agents; D004791:Enzyme Inhibitors; D010091:Oximes; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides